论文部分内容阅读
目的探讨恩替卡韦与干扰素α-1b联合在慢性乙型病毒性肝炎中的应用效果。方法 80例慢性乙型病毒性肝炎患者,随机分为观察组和对照组,每组40例。两组均给予恩替卡韦治疗。观察组同时给予干扰素α-1b治疗。两组均治疗12个月。观察两组患者HBe Ag血清转换率和ALT复常率情况。结果观察组患者治疗后的6个月和12个月的乙型肝炎病毒e抗原(HBe Ag)血清转换率分别高于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的6个月和12个月的ALT复常率分别高于对照组,差异有统计学意义(P<0.05)。结论恩替卡韦与干扰素α-1b联合在慢性乙型病毒性肝炎中的效果显著,值得临床借鉴。
Objective To investigate the combined effect of entecavir and interferon α-1b in chronic hepatitis B virus. Methods Eighty patients with chronic hepatitis B were randomly divided into observation group and control group, 40 cases in each group. Both groups were given entecavir treatment. The observation group was treated with interferon alfa-1b at the same time. Both groups were treated for 12 months. The HBeAg seroconversion rate and ALT normalization rate in both groups were observed. Results The seroconversion rates of hepatitis B virus e antigen (HBeAg) in the observation group at 6 and 12 months after treatment were significantly higher than those in the control group (P <0.05). The recovery rate of ALT at 6 months and 12 months after treatment in the observation group was higher than that in the control group respectively, with significant difference (P <0.05). Conclusion The combination of entecavir and interferon alfa-1b in chronic hepatitis B virus is effective and worthy of clinical reference.